FC
ACAD icon

Financial Consulate’s Acadia Pharmaceuticals ACAD Stock Holding History

Financial Consulate’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10
Closed -$214 – 1341
2025
Q3 		$214 Buy
+10
New +$236 ﹤0.01% 1133

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Financial Consulate's ACAD Position: Q4 2025 in Review

Financial Consulate sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 10 shares — an estimated $214 sold.

Financial Consulate first reported a position in ACAD in Q3 2025 and held it in 1 quarter. The position peaked at $214 in Q3 2025. 334 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Financial Consulate reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Financial Consulate sold 10 Acadia Pharmaceuticals shares in Q4 2025, an estimated $214.
  • Financial Consulate first reported a position in Acadia Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Financial Consulate's Acadia Pharmaceuticals position peaked at $214 in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Financial Consulate's 13F filing for Q4 2025, filed 22 Jan 2026.